Universal Screening Program in Pregnant Women and Newborns at-Risk for Sickle Cell Disease: First Report from Northern Italy

Abstract The implementation of screening programs for early detection of patients with sickle cell disease has become necessary in Italy as a result of the high rate of migration from areas with a high prevalence of the disease (Sub-Saharan Africa, Middle East and the Balkans). Following a pilot study performed in the province of Modena, Italy in 2011–2013, an official screening program was established on May 31 2014 for all pregnant women, free-of-charge for the family according to the National Guidelines for Physiological Pregnancy. Hemoglobin (Hb) profiles of pregnant women within 10 weeks of pregnancy, of new mothers at delivery and of the newborns of mothers with variant Hb profiles (newborns at-risk), were evaluated by high performance liquid chromatography (HPLC). Samples from 17,077 new mothers were analyzed and 993 showed alteration of Hb patterns (5.8%) (1.0% Hb AS carriers); of the 1011 at-risk newborns, four (0.4%) carried sickle cell disease and 90 (8.9%) were Hb AS carriers. These data show that early diagnosis of sickle cell disease or carrier status can be obtained in high-risk newborns, providing valuable information on the frequency of these conditions in geographic areas in which the disease is historically rare.

[1]  P. Paolucci,et al.  Sickle cell disease in areas of immigration of high-risk populations: a low cost and reproducible method of screening in northern Italy. , 2014, Blood transfusion = Trasfusione del sangue.

[2]  A. Tatem,et al.  Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000 , 2014, The Lancet. Global health.

[3]  S. Lobitz,et al.  Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany , 2014, European Journal of Human Genetics.

[4]  M. Zaffaroni,et al.  Neonatal screening for sickle cell disease and other hemoglobinopathies in "the changing Europe". , 2014, Clinical laboratory.

[5]  A. Ferlini,et al.  Universal neonatal screening for sickle cell disease and other haemoglobinopathies in Ferrara, Italy. , 2013, Blood transfusion = Trasfusione del sangue.

[6]  E. Soteriades,et al.  The Impact of Migrations on the Health Services for Rare Diseases in Europe: The Example of Haemoglobin Disorders , 2013, TheScientificWorldJournal.

[7]  M. Westerman,et al.  A case study of haemoglobinopathy screening in the Netherlands: witnessing the past, lessons for the future , 2011, Ethnicity & health.

[8]  R. Latinovic,et al.  Positive screening and carrier results for the England-wide universal newborn sickle cell screening programme by ethnicity and area for 2005–07 , 2010, Journal of Clinical Pathology.

[9]  C. Quinn,et al.  Improved survival of children and adolescents with sickle cell disease. , 2008, Blood.

[10]  P. Lê,et al.  Neonatal haemoglobinopathy screening in Belgium , 2008, Journal of Clinical Pathology.

[11]  J. Bardakdjian‐Michau [Neonatal screening of sickle cell disease in France]. , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[12]  M. Soler,et al.  Evaluación en el tercer año de implantación del cribado neonatal universal de anemia falciforme en la Comunidad de Madrid , 2007 .

[13]  M. García Arias,et al.  [Evaluation of systematic neonatal screening for sickle cell diseases in Madrid three years after its introduction]. , 2007, Anales de pediatria.

[14]  D J Weatherall,et al.  Inherited haemoglobin disorders: an increasing global health problem. , 2001, Bulletin of the World Health Organization.

[15]  P. Fernhoff,et al.  US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN). , 2000, The Journal of pediatrics.

[16]  J. Eastman,et al.  Automated HPLC screening of newborns for sickle cell anemia and other hemoglobinopathies. , 1996, Clinical chemistry.